Idigoras I, Arrospide A, Portillo I, Arana-Arri E, Martínez-Indart L, Mar J, de Koning H J, Lastra R, Soto-Gordoa M, van der Meulen M, Lansdorp-Vogelaar I
Basque Country Colorectal Cancer Screening Programme, the Basque Health Service, Gran Vía, 62 - 4°, 48011, Bilbao, Spain.
BioCruces Health Research Institute, Barakaldo, Spain.
BMC Public Health. 2017 Aug 1;18(1):78. doi: 10.1186/s12889-017-4639-3.
The population-based Basque Colorectal Cancer (CRC) Screening Programme started in 2009 with a biennial immunochemical quantitative test (FIT) biennial and colonoscopy under sedation in positive cases. The population target of 586,700 residents was from 50 to 69 years old and the total coverage was reached at the beginning of 2014. The aim of our study was to determine possible scenarios in terms of incidence, mortality and reduction of Life-years-Lost (L-y-L) in the medium and long term of CRC.
Invitations were sent out by the Programme from 2009 to 2014, with combined organizational strategies. Simulation was done by MISCAN-colon (Microsimulation Screening Analysis) over 30 years comparing the results of screening vs no-screening, taking the population-based Cancer Registry into account. Lifetime population and real data from the Programme were used from 2008 to 2012. The model was run differentially for men and women.
924,416 invitations were sent out from 2009 to 2014. The average participation rate was 68.4%, CRC detection rate was 3.4% and the Advanced Adenoma detection rate was 24.0‰, with differences observed in sex and age. Future scenarios showed a higher decrease of incidence (17.2% vs 14.7%), mortality (28.1% vs 22.4%) and L-y-L (22.6% vs 18.4%) in men than women in 2030.
The Basque Country CRC Programme results are aligned to its strategy and comparable to other programmes. MISCAN model was found to be a useful tool to predict the benefits of the programme in the future. The effectiveness of the Programme has not been formally established as case control studies are required to determine long term benefits from the screening strategy.
基于人群的巴斯克地区结直肠癌(CRC)筛查项目始于2009年,每两年进行一次免疫化学定量检测(FIT),检测呈阳性的病例需在镇静状态下接受结肠镜检查。该项目的目标人群为586,700名年龄在50至69岁之间的居民,到2014年初实现了全面覆盖。我们研究的目的是确定CRC在中长期的发病率、死亡率和生命年损失(L-y-L)减少方面的可能情况。
该项目在2009年至2014年期间发出邀请,并采用了综合组织策略。通过MISCAN - colon(微观模拟筛查分析)进行了30年的模拟,比较了筛查与未筛查的结果,并考虑了基于人群的癌症登记数据。使用了2008年至2012年该项目的终生人群和实际数据。该模型针对男性和女性分别运行。
2009年至2014年共发出924,416份邀请。平均参与率为68.4%,CRC检测率为3.4%,高级腺瘤检测率为24.0‰,在性别和年龄方面存在差异。未来情况显示,到2030年,男性的发病率(17.2%对14.7%)、死亡率(28.1%对22.4%)和L-y-L(22.6%对18.4%)的下降幅度高于女性。
巴斯克地区CRC项目的结果与其策略相符,且与其他项目相当。发现MISCAN模型是预测该项目未来益处的有用工具。由于需要病例对照研究来确定筛查策略的长期益处,该项目的有效性尚未正式确立。